ArticleJournal of Taibah University Medical Sciences2023
Fabrication, optimization and characterization of an osmotic push-pull drug delivery system for paliperidone.
Article in Journal of Taibah University Medical Sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Paliperidone is a BCS class II drug with low solubility and high permeability. It has 28% absolute oral bioavailability and an elimination half-life of 23 h. An osmotic push-pull trilayer tablet currently available on the market has achieved controlled release of a low dose over an extended time period, while avoiding the need for a loading dose. However, this trilayer tablet has several disadvantages, such as complicated processing, high production costs and difficulty in achieving uniformity of the contents. Thus, the objective of this study was to overcome the above difficulties associated with paliperidone and to formulate a bilayer tablet with a similar drug profile to that of the reference listed drug Invega®. Methods: The bilayer tablets were prepared by optimization of the core and semi-permeable membrane. Effects of the curing time, and the size and number of orifices on the prepared tablets' dissolution profile were analyzed. Two different grades of polyethylene oxide were used in the core and push layer as pore formers. Results: The weight variation, friability and hardness values of the prepared tablets were well within compendium limits. The optimized bilayer parameters for the prepared tablets were curing time, 5 h; seal coat, 7% w/w; ER coat, 13% w/w; orifice size, 0.6 mm; and orifice number, 2. Further tablet formulation resulted in an F2 value of 75.67, indicating a dissolution profile similar to that of Invega®. Conclusion: Bi-layer tablets of paliperidone overcoming the drawbacks of the marketed formulation were successfully prepared, and offer advantages such as a simpler preparation process, cost effectiveness and faster preparation of the tablet core.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.